Compare Charles River Laboratories Intl. Inc (CRL) vs Estee Lauder Companies Inc (EL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Estee Lauder Companies Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $299.21 (market cap $14.23B), while Estee Lauder Companies Inc trades at $96.94 (market cap $34.17B). The key difference: Estee Lauder Companies Inc is far larger — about 2.4× Charles River Laboratories Intl. Inc's market cap, and Estee Lauder Companies Inc pays a 1.48% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Estee Lauder Companies Inc for 122 Days on average.
| CRL | EL | |
|---|---|---|
Market Cap | $14.23B | $34.17B |
Volume | 1,176,885 | 3,921,497 |
Sector | Health | Consumer Staples |
52-Week High | $310.77 | $119.61 |
52-Week Low | $149.93 | $67.23 |
Typical Hold Time | 33 Days | 122 Days |
Enterprise Value | $17.06B | $39.92B |
Dividend Yield | — | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.30, down 1.53% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus target. The stock maintains a bullish technical signal with support at $295 and resistance at $306. Recent earnings have consistently beaten expectations, though the company faces profitability challenges with negative net income margins and elevated valuation multiples.
While CRL shows promising growth initiatives including 5-7% revenue targets and $300M savings by 2030, investors face risks from negative profitability, high debt levels, and premium valuations. The stock's near-term catalyst will be Q3 2026 earnings against $2.97 EPS expectations, with technical positioning suggesting limited downside from current levels.
Estée Lauder (EL) trades at $94.45, up 1.17% with a bullish technical signal from moving averages. The company shows improving earnings momentum with three consecutive quarterly beats, though 2025 results showed a net loss of $1.13B on $14.33B revenue. Analyst consensus is mixed with 48% buy ratings and a $103 price target, while recent news highlights AI partnerships and leadership changes driving strategic repositioning.
The stock presents a turnaround opportunity with strong brand positioning and digital initiatives, but faces execution risks from recent profitability challenges and high debt levels. Near-term catalysts include Q3 earnings and continued margin recovery, though competitive pressures and macroeconomic sensitivity remain headwinds for the luxury beauty sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →
